Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.63 |
| ▸ | NAMPT | P43490 | 8/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038840 | 0.84 | NAMPT (0.81) | CYP11B1CYP11B2NAMPTLMNAHIF1A | |
| SCHEMBL3031316 | 0.82 | HDAC2 (0.74) | NPC1RAB9AKDM4E | |
| SCHEMBL30533390 | 0.81 | LMNA (0.81) | CYP11B1CYP11B2NAMPTSIRT2LMNA | |
| SCHEMBL7405091 | 0.80 | RAB9A (0.78) | LMNANPC1RAB9AGAAKDM4E | |
| SCHEMBL13095736 | 0.78 | CYP11B1 (0.68) | CYP11B1CYP11B2NAMPTLMNAHIF1A | |
| Hydrochloric Acid SCHEMBL27467353 | 0.78 | NAMPT (0.57) | CYP11B1CYP11B2NAMPTSIRT2LMNA | |
| SCHEMBL6354168 | 0.78 | CYP11B1 (1.00) | CYP11B1CYP11B2NAMPTLMNAHIF1A | |
| SCHEMBL4089884 | 0.77 | NAMPT (0.81) | CYP11B1CYP11B2NAMPTSIRT2LMNA | |
| SCHEMBL5412469 | 0.77 | ROCK2 (0.64) | CYP11B1CYP11B2NAMPTNPC1RAB9A | |
| SCHEMBL6027553 | 0.77 | HDAC1 (0.51) | NAMPTNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | claimed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | CYP11B1 1222/4885CYP11B2 1466/4885NAMPT 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.